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Abstract
Background: A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of
drug resistance, particularly from individuals who are HIV-infected but unaware of their status. Limited data exist on the
prevalence of HIV infection or drug resistance among potential users of ARV-based prevention products.
Methods: A cross-sectional study of reproductive-aged women who presented to screen for an HIV prevention trial was
conducted at 7 clinical sites in Durban, South Africa. CD4+T cell counts, HIV-1 RNA levels and population sequencing of the
protease and reverse transcriptase genes were performed for all women with 2 positive HIV rapid tests. Resistance
mutations were identified using the Stanford Calibrated Population Resistance Tool.
Results: Of the 1073 evaluable women, 400(37%) were confirmed as HIV-infected. Of those, plasma HIV-1 RNA was
detectable in 365/400(91%) and undetectable(,40 copies/ml) in 35/400(9%) women. 156 women(39%) were eligible for
antiretroviral therapy (CD4+T cell counts,350 cells/mm3) and 50(13%) met criteria for AIDS(CD4,200 cells/mm3). Of 352
plasma samples(.200 copies/ml) analyzed for drug resistance, 26(7.4%) had nucleoside reverse transcriptase inhibitor
(NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) drug resistance mutations. Among
those with resistance, 18/26 participants(62%) had single-class NNRTI resistance and 5/26(19%) had dual-class NRTI/NNRTI.
Major mutations in reverse transcriptase included K65R(n = 1), L74I(n = 1), K103N(n = 19), V106M(n = 4), Y181C(n = 2),
M184V(n = 4), and K219E/R(n = 2). Major PI-resistance mutations were rare: M46L(n = 1) and I85V(n = 1). All participants were
infected with subtype C virus, except one infected with subtype A.
Conclusions: In women from Durban, South Africa screening for an HIV prevention trial, the HIV prevalence was high (37%)
and HIV drug resistance prevalence was above 5%. This study highlights the potential challenges faced when implementing
an ARV-based prevention product that overlaps with first-line antiretroviral therapy. Effective screening to exclude HIV
infection among women interested in uptake of ARV-based HIV prevention will be essential in limiting the spread of ARV
resistance.
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Introduction
Women are disproportionately burdened by human immuno-
deficiency virus (HIV) infection, particularly in sub-Saharan
Africa, where approximately three-quarters of new HIV-1
infections are in young women aged 15–24 years [1,2]. Recent
clinical trials evaluating tenofovir as a potential chemo-preventa-
tive agent have screened thousands of women for participation in
large-scale studies including FEM-PrEP, CAPRISA-004, TDF2
and MTN-003 (VOICE) [3]. Inevitably, some women who present
to the clinic intending to participate in an HIV-prevention trial
discover they are HIV positive or already have knowledge of their
status but still seek HIV prevention products or trial participation
for other reasons [4]. This group of women is critical to
understand both from a virologic and behavioral perspective
because the future success and large scale implementation of an
ARV product for HIV prevention largely depends on targeting the
appropriate population for its use.
One of the major concerns of using ARV-based products for
HIV prevention is the potential for drug resistance, particularly in
individuals who are HIV infected and unaware of their status. In a
survey of 5821 women and men from 16 rural communities in
KwaZulu-Natal South Africa, 68% reported they had never been
tested for HIV [5]. A recent modeling analysis identified
inadvertent PrEP use by already-infected individuals as having
the greatest influence on the potential for emergence and spread of
resistance arising from PrEP rollout [6]. To date, the 5 cases of
resistance that have occurred in a total of 172 seroconverters from
the use of tenofovir-based pre-exposure prophylaxis (PrEP) have
been from participants on active antiretroviral (ARV) arms who
enrolled during the acute phase of infection: 0/35 in the TFV gel
arm in CAPRISA-004 [7]; 2/36 in the oral TDF-FTC arm in
iPrEX [8], 1/9 in the TDF2 study [9], and 2/92 from the Partners
in PrEP serodiscordant couple study, where 1 case occurred in the
TDF arm, and 1 case occurred in the TDF-FTC arm [10].
Transmitted resistance in the general population could also
potentially compromise the success of ARV-based prevention if
circulating variants are resistant to the products used for topical or
oral agents. While most studies conducted in sub-Saharan Africa
thus far have identified low rates of transmitted ARV resistance,
mathematical modeling and experience from resource-rich coun-
tries suggest that once antiretroviral therapy (ART) coverage
increases, the rate may rise [11,12]. In South Africa, the frequency
of transmitted resistance has been variable: 1.1% in Pretoria, 4.5%
in Johannesburg, 4.8% in White River and as high as 9.3% in
Northeastern South Africa [13,14]. An analysis of 1690 sequences
from recent seroconverters in KwaZulu-Natal reported the
prevalence of resistance as ,5% [15]. Recent surveys using the
WHO threshold surveillance method of treatment-naı¨ve and/or
recently diagnosed pregnant women from antenatal clinics in
KwaZulu-Natal have reported low resistance prevalence of ,5%
but increasing to 5–15% for NNRTIs [16,17].
The objective of MTN-009 was to provide a current estimate of
the prevalence of ARV resistance in a subset of women screening
to participate in HIV prevention trials.
Methods
Design
MTN-009 was a cross-sectional study conducted at seven sites of
the HIV Prevention Research Unit, Medical Research Council
between September 2010 and March 2011. Clinical sites are
located in semi-rural and urban areas in the greater Durban area
of KwaZulu-Natal. These include Botha’s Hill, Chatsworth,
Isipingo, Overport, Tongaat, Umkomaas, and Verulam. Partici-
pants were not specifically recruited for MTN-009, but interest in
participation in this study was sought among those who presented
to the study site to screen for the VOICE/MTN-003 trial and
whose HIV status was unknown. VOICE is a phase 2B safety and
effectiveness study of tenofovir 1% gel, tenofovir disoproxil
fumarate (TDF) tablet and emtricitabine/TDF tablet for the
prevention of HIV infection in women (http://www.mtnstopshiv.
org/studies/70). The target sample size for MTN-009 was 1000
women aged 18–40 years to enroll 350 HIV positive evaluable
participants. As shown in Figure 1, after obtaining informed
consent, women enrolled in MTN-009 and underwent an audio
computer assisted self-interview questionnaire (ACASI) before
rapid testing for HIV to determine HIV status by serology. All
participants were counseled, and those with two negative rapid
tests were referred to the VOICE study, while those who were
seropositive underwent additional laboratory testing described
below. The protocol, informed consent forms, and all study
materials were reviewed and approved by the National Institute of
Allergy and Infectious Diseases Division of AIDS (NIAID/
DAIDS) in the United States, and by the Medical Research
Council Ethics Committee in South Africa. The MTN-009 study
was registered at www.Clinical-Trials.gov (NCT01204814) and
the protocol can be found at http://www.mtnstopshiv.org. All
participants provided written informed consent to participate in
this study.
Laboratory Methods
Two simultaneously performed HIV rapid tests, at least one
of which was FDA-approved (Determine, Abbott Laboratories,
Johannesburg, SA; Unigold, Trinity Biotech, Wicklow, Ireland;
or Oraquick, OraSure Technologies, Bethlehem, PA) were used
to identify MTN-009 participants as HIV-1 seropositive.
Infection was confirmed by the Bio-Rad GS HIV-1/2+O
Enzyme Immunoassay (Hercules, CA). In addition, Bio-Rad GS
HIV-1 Western blot was used to confirm infection status for
participants with either discordant rapids or with dual positive
rapids and undetectable HIV-1 RNA (,40 copies/ml). Plasma
HIV-1 RNA levels (with a lower limit of detection of 40 copies/
ml) using the m2000 RealTime HIV-1 system (Abbott Labora-
tories, Abbott Park, IL) and CD4+ T cell counts using the
FACS calibur (BD diagnostics, Woodmead, Gauteng, South
Africa) were determined for all HIV positive participants.
Plasma HIV-1 genotyping was attempted for all participants
with RNA levels .200 copies/ml using the ViroSeq 2.0
Genotyping Method (Celera, Alameda, CA) which targets
sequencing of the entire protease gene from amino acids 1–99
and two thirds of the reverse transcriptase gene from amino acids
1–335. The 36 samples that did not amplify with FDA-
approved primers provided with the ViroSeq kit, or that did not
successfully sequence with at least 5 bi-directional overlapping
primers were re-amplified and/or re-sequenced using in-house
primers provided by Celera. RNA from samples with low viral
RNA levels (200–1000 copies/ml) were concentrated before
performing RT-PCR. All sequences were manually edited and
nucleotide positions with multiple peaks present at greater than
20% above background were considered mixtures. Resistance
mutations were identified using the Stanford Calibrated
Population Resistance Tool [18] and samples were considered
to be resistant if they contained one or more mutations as
defined by the Bennett WHO list of transmitted resistance [19].
Samples were subtyped using the Rega Subtyping tool.
Participants with CD4+ T cell counts of ,200 cells/mm3 and
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resistance mutations were counseled on what the test measured
and what the results signify.
Statistical Methods
Descriptive statistics were used to summarize characteristics of
the cohort and the prevalence and types of resistance mutations.
Specifically, the number and percentage in each category were
determined for categorical variables, and the mean, median,
standard deviation, quartiles and range (minimum, maximum)
were calculated for continuous variables. The exact 95%
confidence interval for the prevalence of resistance was calculated
using the Clopper-Pearson method for a binomial distribution.
Results
Study Population
1075 women who presented to screen for VOICE were offered
participation and subsequently enrolled in MTN-009; no woman
declined enrollment. Two participants were excluded due to
enrollment violations: 1) above age 40, and 2) revealed prior
knowledge of HIV positive status after enrollment (Figure 2). Of
the remaining 1073 participants, the mean age was 25.6 years, and
predominant race was Zulu (87%). Almost all participants (1015
[99%]) reported having a primary sex partner but only 43 (4%)
reported being married. Most participants earned their own
income (70%) and had at least some secondary school education
(92%). The mean number of children born to participants was
1.461.1 (Table 1). More than a third of participants (400/1073)
were confirmed to be HIV-1 positive, resulting in a prevalence of
37% in the MTN-009 study population.
CD4+ T Cell Counts and HIV-1 RNA Levels
Of 400 HIV-1 positive participants, 244 (61%) had CD4+ T cell
counts above 350 cells/mm3 (Figure 3). 156 (39%) had CD4
counts below 350 cells/mm3 indicating eligibility for antiretroviral
treatment if pregnant, co-infected with tuberculosis or in WHO
clinical state IV according to the South African guidelines at the
time period during which the study took place (September 2010–
March 2011) [20]. Fifty women (13%) had CD4 counts below 200
cells/mm3. These participants met ART eligibility in South Africa
irrespective of clinical stage [20] and are considered to have AIDS
according to the Center for Disease Control and Prevention’s
AIDS surveillance case definition [21].
Plasma HIV-1 RNA levels ranged from undetectable (,40) to
2,674,072 copies/ml. Excluding those with undetectable values,
mean and median HIV-1 RNA copies/ml were 75,449 and
18,924 copies/ml respectively. Plasma HIV-1 RNA copies/ml
were below detectable range in 35/400 (8.8%) of participants, and
an additional 12 participants (3%) had detectable HIV-1 RNA
levels that were at or below 200 copies/ml (Figure 3).
Antiretroviral Resistance
Most participants (352/400 [88%]) had HIV-1 RNA levels
above 200 copies/ml and plasma virus from all but one was
successfully sequenced for determination of HIV resistance using
standard, commercially-available genotyping methods to identify
mutations in the reverse transcriptase and protease genes in the HIV-1
polymerase region. The majority of samples (326 [92.6%]) had
HIV-1 with no known ARV resistance mutations, whereas 26
(7.4%; 95% CI [4.9, 10.6]) had at least one known ARV-resistance
mutation, as defined by the World Health Organization (WHO)
Figure 1. MTN-009 Study Schema.
doi:10.1371/journal.pone.0059787.g001
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list of transmitted drug resistance [19] (Figure 4). K103N was the
most frequently detected mutation, present in 19/26 samples
having drug resistance (73%). There were also multiple occur-
rences of V106M (n = 4), M184V (n = 4), Y181C (n = 2) and
G190A (n = 2). The following mutations were detected in only one
sample each: M46L and I85V (protease); K65R, L74I, K219E/R,
Table 1. Demographic Factors for All Evaluable Participants and the Subset that was HIV Positive and Tested for Drug Resistance
in MTN-009.
Participant Factors All Evaluable Participants (N=1073) HIV+ & tested for resistance (N=352)
Mean age, years (SD) 25.6 (5.6) 26.8 (5.4)
Married 43 (4%) 11 (3%)
Has a primary sex partner 1015 (99%) 335 (98%)
Living with husband/primary sex partner 200 (19%) 63 (18%)
Earns her own income 747 (70%) 243 (69%)
Has at least some secondary school education 987 (92%) 315 (89%)
Mean (SD) number of children given birth to 1.4 (1.1) 1.4 (1.1)
Race
Zulu 931 (87%) 300 (85%)
Xhosa 111 (10%) 45 (13%)
Indian 12 (1%) 0 (0%)
Other 17 (2%) 7 (2%)
Notes: SD = Standard Deviation.
doi:10.1371/journal.pone.0059787.t001
Figure 2. Consort Diagram.
doi:10.1371/journal.pone.0059787.g002
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and K101E (reverse transcriptase) (Figure 4). Eighteen samples
(69%) only had one resistance mutation, four samples had two
resistance mutations, and four samples had three or more
resistance mutations. Twenty samples had mutations from a single
class, while the remaining six had dual-class resistance mutations.
No samples harbored resistance to all three drug classes (NRTI,
NNRTI, PI) (Table 2). Of the three drug classes, resistance to
NNRTI class of HIV inhibitors was most frequent. All participants
were infected with subtype C HIV-1, except one, who was infected
with subtype A.
Discussion
MTN-009 is the first study to evaluate the prevalence of HIV
infection and the proportion of drug-resistant infection in a
population of women screening for participation in an ARV-based
HIV prevention trial. Several recent surveys conducted in different
regions of South Africa among diverse populations have reported
that the prevalence of HIV infection among women aged 14–35
years ranges from 22% in the Mbekweni district to as high as
59.3% amongst urban women in the Hlabisa district [22–24]. The
prevalence of HIV in MTN-009 was 37%, consistent with other
recent reports, but higher than anticipated in women interested in
participating in HIV prevention trials.
The high HIV prevalence in a prevention trial screening
population suggests several possibilities: 1) many women in
KwaZulu-Natal still do not know their HIV status; 2) many
women who have had an HIV test may want confirmation of their
status; 3) many women may be reluctant to report their status
because of stigma associated with being HIV positive and/or; 4)
HIV positive women may present for screening to HIV prevention
studies because they are seeking ART or access to better health
care and hope for referrals. Indeed, 39% of women in MTN-009
had CD4+ T cell counts qualifying them for ART (,350 cell/
mm3), and 12.5% women had CD4 counts low enough to increase
risk of AIDS (,200 cells/mm3), suggesting either a long duration
of unrecognized infection or denial of or unwillingness to report
one’s HIV status.
The continued high prevalence of HIV combined with
unreliable self-reports of HIV status, particularly in a population
targeted for HIV prevention trials, highlights both the need for an
effective prevention agent and the importance of improved HIV
testing before ARV-based prevention products are disseminated
for widespread use. Modeling studies show that the greatest
determinant of drug resistance prevalence arising from PrEP is
from use of oral PrEP by previously-infected individuals [6].
However, the MTN-009 study aimed to avoid enrolling women
who already knew their HIV status. Inclusion criteria involved
asking a potential participant about her desire for prevention trial
participation. Women were not directly recruited for this study,
but rather, some women who presented at sites to screen for a
Figure 3. CD4+ T Cell Counts and HIV-1 RNA Levels of HIV-1 Positive Participants. Histogram showing frequency of HIV positive
participants (n = 400) that have (A) CD4+ T cell counts,200 cells/mm3 indicating risk for AIDS, 200–349 cells/mm3 indicating treatment eligibility, and
.350 cells/mm3; and (B) varying levels of HIV-1 RNA (copies/ml).
doi:10.1371/journal.pone.0059787.g003
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Phase 2B prevention trial evaluating safety and efficacy of
tenofovir-based oral tablets or vaginal gel (VOICE) were offered
participation in MTN-009. By not advertising MTN-009 in the
community, we aimed to avoid enrollment of women who simply
wanted a drug resistance test, which is not widely available as part
of routine clinical management of HIV positive patients. Although
some women may have enrolled into MTN-009 for the benefit of
receiving HIV monitoring test results including CD4, HIV RNA
or drug resistance, we believe the majority of women who were
HIV positive did not knowingly enroll as such.
An unexpectedly high proportion of HIV positive women (35/
400 or 8.8%) who were presumed to be untreated had
undetectable HIV-1 RNA levels (,40 copies/ml). CD4+ T counts
for these participants ranged from 121–1141 cells/mm3. An
additional 12 participants had detectable RNA levels too low to
perform resistance testing (,200 copies/ml). Elite control of HIV
infection, which is the spontaneous suppression of plasma viremia
with maintenance of high CD4+ T cell levels in the absence of use
of antiretroviral agents, occurs in less than 1% of HIV-infected
individuals [25]. Consequently, elite control is unlikely to explain
the high proportion of participants with very low or undetectable
viremia. Knowledge of treatment history, plasma drug levels and
long-term follow up of MTN-009 participants is needed to
determine if the cause of frequent undetectable HIV-1 RNA is due
to antiretroviral use by some participants. Because CD4+ T cells
counts are more widely used than HIV RNA in the public sector
for monitoring patients on therapy, it is possible that some
participants who were already taking ART may have joined the
study because they were interested in receiving both an HIV RNA
and a CD4 T cell count results to assess their clinical status.
Of the 352 participants with HIV genotypes, 26 (7.4%) were
found to have at least one NRTI or NNRTI resistance mutation as
identified from the World Health Organization (WHO) list of
transmitted resistance [19]. This level of resistance is greater than
the ,5% range for South Africa first classified in 2008 using the
WHO drug resistance threshold survey method, and recently
upheld in an analysis of 72 seroconverter sequences from Africa
Centre’s 2010 surveillance round [15,26]. Manasa et al. concluded
that there is no transmitted drug resistance in KwaZulu-Natal
[15]. However our findings verify results from Hunt et al. who
determined that transmitted resistance in the Gauteng province
remains low at ,5%, but NNRTI resistance is increasing in
KwaZulu-Natal, elevating the threshold classification from low to
moderate (5–15%) for that region [17,27].
Figure 4. Frequency of ARV Resistance Mutations. Histogram showing number of women with drug resistant HIV infection that had each of
the following protease inhibitor (PI), nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)
mutations M46L, I85V, K65R, L74I, K219E, M184V, K101E, V106M, Y181C or G190A. Resistance mutations were identified using the Stanford Calibrated
Population Resistance Tool.
doi:10.1371/journal.pone.0059787.g004
Table 2. Major Drug Resistance Mutation Profiles Detected.
Number of
Participants Resistance Profile
NRTI NNRTI PI
1 K219R – –
1 K219E – –
14 – K103N –
1 – V106M –
1 – – M46L
1 – K103N, Y181C –
1 – V106M, G190A –
1 K65R Y181C –
1 M184V K103N –
1 M184V K101E, K103N –
1 M184V K103N, V106M –
1 L74I, M184V K103N –
1 – K101E, V106M, G190A I85V
doi:10.1371/journal.pone.0059787.t002
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Indeed, the most commonly occurring mutation in our study
was the NNRTI mutation K103N, which was the only mutation
present in virus from 14 women; an additional 5 women had HIV
with K103N and other NRTI or NNRTI mutations. Possible
sources of K103N acquisition include transmission from a partner
on first line therapy in South Africa which includes nevirapine or
efavirenz, or selection of resistance from prior exposure to
nevirapine for prevention of mother to child transmission
(PMTCT) [28]. In a survey of 882 post-partum mothers in
antenatal wards in KwaZulu-Natal, 98.6% women reported
receiving antenatal care, but only 42.1% of the 312 mothers
found to be HIV positive received follow-up care [29]. It is
possible that some women in MTN-009 could have been provided
single dose nevirapine for prevention of MTCT during delivery in
a facility but were not clear on the purpose. From the current data,
the origin of NNRTI resistance cannot be determined.
Some participants (5/26, 19%) had resistance profiles that
included one or more mutations from both the NRTI and NNRTI
classes (Table 2) suggesting that these women may have at one
point been on ART or had transmitted drug resistance from a
partner on incompletely suppressive ART. Misclassification of
ARV treatment status could overestimate resistance prevalence in
cross-sectional cohorts [30]. This study relied on participant self-
report and could not objectively verify self-knowledge of partic-
ipant HIV status or prior treatment history to accurately classify
resistance observed as transmitted or selected.
Although we cannot be certain that resistance identified in this
population was transmitted, we did ask all women via ACASI if
she had even been prescribed ARVs and 97% of participants said
that they had not. This does not represent an extensive drug
history, but it was a confidential one in which the data were
collected using a method that was thought to maximize reporting
of information that would be less likely to be obtained through a
face-to-face interview with a clinician [31,32]. We do allow for the
possibility that some women took ARVs unknowingly, possibly
during labor and delivery for the purpose of prevention of
transmission to an infant, if they were tested during labor and not
clearly informed of the result of their HIV test or did not
understand the result during labor and delivery.
This study has some limitations. Because of the cross-sectional
design, follow-up of HIV positive participants could not be done to
determine whether resistance persisted or to ensure that partic-
ipants with low CD4 counts or with ARV resistance subsequently
accessed HIV treatment and care. Much effort was undertaken to
actively follow-up referrals given by the study clinician. Although
clinic staff conducted three telephone calls and one home visit, all
participants could not be reached to assess the outcome of the
referral. Secondly, the study population was enrolled between
2010–2011, just after the changes in the South African national
treatment guidelines in 2010 introducing tenofovir as part of first
line therapy. We expect that tenofovir may not have been used
extensively enough as treatment for HIV infected individuals
during the period of participant enrollment to influence the study
results. This may explain why the frequency of resistance with
K65R was found to be low (,1%) in this study. The frequency of
K65R may change over time with increased tenofovir use for first-
line HIV treatment. Several studies have indicated that K65R may
be more readily selected in subtype C virus, or may be
polymorphic at low frequencies [33].
Overall, MTN-009 provides important data on the background
of resistance in the setting in which an ARV-based product may
eventually be widely disseminated for prevention use. With the
increase in ARV use both for treatment and prevention, it will be
critical to continue monitoring drug resistance both in clinical trial
settings in seroconverters from ARV-based prevention trials, and
also in community hospitals and clinics in treatment-naı¨ve and
experienced individuals. The dominance of NNRTI resistance in
the prevention trial screening population suggests that current
ARV-based prevention strategies that include tenofovir will
continue to be active in this cohort, but studies evaluating first
line treatment failures for cross-resistance with other NNRTI
under consideration for use as ARV-based prevention are a high
priority.
In addition, this study enables a better understanding of the
population of women interested in screening for HIV prevention
trials, and women interesting in accessing ARV-based HIV
prevention products, which at this point, is only available through
a trial setting. By evaluating the prevalence of drug resistant virus
in this population, we will be able to better understand the
challenges that could be faced when implementing a successful
ART-based prevention product. In roll-out of such a product, it is
possible that women who know their status, are already on ART,
or were previously exposed to ARVs unknowingly would still seek
access to HIV prevention. Individuals already harboring drug
resistant virus may have additional risk in using ARV-based
products meant for prevention.
Further, there are implications for HIV treatment if the
prevalence of resistance is increasing in the population. To
preserve the effectiveness of tenofovir as first-line therapy, it will be
important to continue surveillance in populations where HIV
incidence is high and where treatment and prevention roll-outs
may be occurring simultaneously.
Finally, this study emphasizes the need for frequent and routine
HIV counseling and testing, particularly in settings of high HIV
prevalence. ARV-based prevention has great potential to reduce
the burden of the HIV epidemic, and the best way to minimize
resistance with ARV-based prevention products is avoid its use in
HIV-infected individuals [6].
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